have had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day for the previous 6 months'. Omalizumab eligibility defined as 'evidence of severe persistent allergic asthma and need for continuous or frequent treatment with oral corticosteroids (defined as 4 courses in the previous year), and meeting bodyweight and IgE criteria for omalizumab treatment'. Results Of 748 SA subjects enrolled in the study, 670 met the analysis criteria and were included in this post-hoc analysis (mean age=50.9 years; 62% female). 90 subjects (13%) were eligible for mepolizumab and 184 (27%) were eligible for omalizumab. Of the 90 mepolizumab eligible patients, 31 (5%) were receiving omalizumab therapy, while of the remaining 59 (9%) patients not on a biologic 11 (2%) were also eligible for omalizumab. Conclusions This is the first cross-sectional study providing estimation of the proportion of SA patients eligible for biologic therapy in accordance with NICE guidance, indicating 13% mepolizumab-eligibility and 27% omalizumab-eligibility with limited overlap. (Funded by GSK; 2 01 722.)
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MONITORING INHALED CORTICOSTEROID ADHERENCE OF PATIENTS ON OMALIZUMAB IN A REAL WORLD COHORT
LJ Holmes, R Daly, K Hince, C Ustabashi, DJ Allen. University Hospital of South Manchester, Manchester, UK Objective To identify barriers which prevent patients meeting the NICE criteria for mepolizumab. Background Mepolizumab is a steroid sparing agent for patients with severe eosinophilic asthma. All patients must meet the NICE 1 criteria:
. 
